

Public disclosure of inside information according to Article 17 of MAR**Updated preliminary sales revenue data for H1 2026**

Sofia, Bulgaria, July 22, 2026 – “Sopharma” AD (SFA: “Bulgarian Stock Exchange” AD, SPH: Warsaw Stock Exchange) pursuant to the requirements of art. 100t of the Law on Public Offering of Securities (LPOS), announces that for the period from the beginning of 2026, the Company achieved sales growth of 45%, including a 3% decrease in domestic sales and sales growth of 74% in export.

Pelagia Viatcheva, Investor Relations Director

Information about Sopharma AD

Sopharma AD is a leading Bulgarian pharmaceutical company with more than 90 years of experience in the development, manufacturing and marketing of pharmaceutical products. The Company operates in accordance with European Good Manufacturing Practice (GMP) standards and is among the largest public companies by market capitalization on the Bulgarian Stock Exchange.

Sopharma's activities include the development, manufacturing and commercialization of medicinal products, active pharmaceutical ingredients and other health related products, scientific research and development in the fields of chemistry, pharmacy and phytochemistry, as well as the production of medical devices and cosmetic products.

Sopharma Group is a vertically integrated healthcare group operating across the pharmaceutical value chain, including pharmaceutical manufacturing, wholesale distribution, retail pharmacy, hospital supplies and related healthcare services. Through its integrated business model, the Group serves patients and healthcare professionals across numerous markets in Central and Eastern Europe and other international markets.